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Objectives: Diabetes leads to cognitive impairment and is associated with age-
related neurodegenerative diseases including Alzheimer’s disease (AD). Thus,
understanding diabetes-induced alterations in brain function is important for
developing early interventions for neurodegeneration. Low-capacity runner
(LCR) rats are obese and manifest metabolic risk factors resembling human
“impaired glucose tolerance” or metabolic syndrome. We examined hippocam-
pal function in aged LCR rats compared to their high-capacity runner (HCR)
rat counterparts. Methods: Hippocampal function was examined using proton
magnetic resonance spectroscopy and imaging, unbiased stereology analysis,
and a Y maze. Changes in the mitochondrial respiratory chain function and
levels of hyperphosphorylated tau and mitochondrial transcriptional regulators
were examined. Results: The levels of glutamate, myo-inositol, taurine, and cho-
line-containing compounds were significantly increased in the aged LCR rats.
We observed a significant loss of hippocampal neurons and impaired cognitive
function in aged LCR rats. Respiratory chain function and activity were
significantly decreased in the aged LCR rats. Hyperphosphorylated tau was
accumulated within mitochondria and peroxisome proliferator-activated recep-
tor-gamma coactivator 1a, the NAD+-dependent protein deacetylase sirtuin 1,
and mitochondrial transcription factor A were downregulated in the aged LCR
rat hippocampus. Interpretation: These data provide evidence of a neurodegen-
erative process in the hippocampus of aged LCR rats, consistent with those seen
in aged-related dementing illnesses such as AD in humans. The metabolic and
mitochondrial abnormalities observed in LCR rat hippocampus are similar to
well-described mechanisms that lead to diabetic neuropathy and may provide
an important link between cognitive and metabolic dysfunction.
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Introduction
Obesity and type II diabetes are among the fastest
growing epidemics in modern times.1 Convincing clini-
cal, epidemiological, and genetic studies have provided
substantial evidence supporting a link between type 2
diabetes and neurodegenerative diseases such as Alzhei-
mer’s disease (AD).2–4 It is also suggested that AD may
represent a consequence of a distinct form of brain-spe-
cific insulin resistance and impaired glucose regulation.
In the Rotterdam study of 6370 elderly subjects, 126
developed dementia of which 89 specifically had AD.5
Type 2-diabetes (T2DM) doubled the risk of a patient
having dementia and patients on insulin had four times
the risk.5 Even in patients who do not have AD or dia-
betes, the presence of a mild increase in the high aver-
age glucose (6.4 mmol/L as compared with 5.5 mmol/
L) over a moderate period of time significantly
increases the risk of dementia.6 This increased risk of
dementia is of considerable impact on societies already
facing epidemic levels of diabetes and impaired glucose
tolerance.
Dysfunctional aerobic energy metabolism has been
implicated in diabetes and age-related neurodegenerative
disease. To study the contribution of aerobic exercise
capacity to the etiology of complex disease states such as
AD, we have developed animal models generated by arti-
ficial selection for low and high aerobic exercise capacity.7
In these animal models, 11 generations of selection
resulted in a 347% difference in running capacity between
LCR and HCR rats.7 LCR rats have impaired metabolic
function, including obesity, insulin resistance, and dyslipi-
demia.8 In LCR rats, there is a significantly low metabolic
flexibility.9 In contrast, HCR rats are lean and have a
nonpathologic metabolic profile.
Neuronal loss, cognitive decline, hypometabolism,
mitochondrial abnormality, and accumulation of hyper-
phosphorylated (p-Tau) have been reported in AD
brain.10,11 Microtubule-associated protein tau is critical
for normal neuronal activity in the brain. Tau is abnor-
mally hyperphosphorylated (p-Tau) in the brains of AD
and experimental diabetes, which is associated with
degeneration of neurons and cognitive impairment.12–14
Mitochondrial abnormalities are found in diabetes and
neurodegenerative diseases including AD.11,15,16 Previous
studies have showed a reduction in glucose metabolism
and a deficiency in respiratory chain complexes includ-
ing complex III in diabetes and AD patients.10,17–19
PGC-1a, SIRT1, and TFAM are recognized to have a
primary role in mitochondrial biogenesis and oxidative
phosphorylation. Reduced PGC-1a expression is shown
to be linked to insulin resistance, type 2 diabetes, and
neurodegenerative disease.20–23 PGC-1a overexpression
protects neurons against oxidative stress by inducing
antioxidant enzymes.24 A recent study demonstrates that
a novel brain PGC-1a isoform (35 kDa) localizes to
hippocampal mitochondria and is associated with
PTEN-induced putative kinase 1 (PINK1) and voltage-
dependent anion channel, suggesting a possible new reg-
ulatory role for mitochondrial function in brain.25
TFAM is the main determinant of the quantity of mito-
chondrial DNA.26 In the TFAM knockout mice, there is
a severe reduction in mitochondrial DNA, disruption of
the electron transport chain, and increased mitochon-
drial oxidative stress.27 Recent publications demonstrate
that elevated SIRT1 levels have implications for the
treatment of type II diabetes, and prevention of neuro-
degenerative diseases.28–30 The putative benefits of exer-
cise for maximizing cognitive function and supporting
brain health have great potential for combating AD.31
We conclude that aerobic exercise may reduce AD
symptoms and appears effective in decreasing caregiver
distress.32
To study the contribution of intrinsic aerobic exercise
capacity upon aging to hippocampal integrity, we mea-
sured hippocampal volume, neuronal number, metabolic
profile, mitochondrial function, and neurobehavioral
studies. Here, we demonstrate that metabolic impair-
ments resulting from genetic factors (selection on low
intrinsic aerobic capacity) upon aging lead to hippo-
campal neurodegeneration, similar to AD. Furthermore,
this study suggests mitochondrial dysfunction as a
potential mechanism for hippocampal neuronal loss in
LCR rats.
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Materials and Methods
Animals
All animal procedures were approved by the Institutional
Animal Care and Use committee at the University of
Maryland School of Medicine, the VA Maryland Health
Care System, and the University of Michigan and were
in accordance with the NIH Guide for the Care and Use
of Laboratory Animals. LCR and HCR rats were derived
from genetically heterogeneous N:NIH stock rats by
artificial selection for low and high treadmill running
capacity as described previously.7 Rats were phenotyped
for intrinsic (i.e., inborn) running capacity at 11 weeks
of age using an incremental treadmill running test. The
single best daily run of three trials for each rat was
considered the trial most closely associated with the
heritable component of endurance running capacity and
used to calculate aerobic exercise capacity in the form
of work performed (joules). Rats were housed under
approved conditions with a 12-h light/dark cycle with
free access to food and water. Animals were provided
with standard chow diets and water ad libitum. Aged
male LCR and HCR rats (~25 months old) were used
for this study.
Metabolic measurements
Metabolic studies were conducted by the University of
Maryland School of Medicine Mid-Atlantic Nutrition
Obesity Research Core and University of Michigan Ani-
mal Phenotyping Core. Mice were euthanized and blood
was collected. The blood was centrifuged and plasma
collected. A 50-lL sample from each mouse was col-
lected for glucose, insulin, cholesterol, and triglyceride
measurements using a colorimetric kit (Diagnostic Che-
micals Ltd.,Waltham, MA U.S.A.). Oxygen consumption
(VO2), carbon dioxide production (VCO2), and sponta-
neous motor activity were measured using the Compre-
hensive Laboratory Monitoring System (CLAMS;
Columbus Instruments, Columbus, OH, U.S.A), an inte-
grated open-circuit calorimeter equipped with an optical
beam activity monitoring device. The CLAMS measure-
ments were carried out continuously for 48–72 hours.
Respiratory quotient (RQ) was calculated as ratio of
VCO2/VO2. Body composition was measured using an
NMR analyzer (Minispec LF90II; Bruker Optics, Water-
town, MA, U.S.A.).
In vivo MRS/MRI experiments
In vivo MRS experiments were performed on a Bruker
BioSpec 70/30USR Avance III 7T horizontal bore MR
scanner (Bruker Biospin, MRI GmbH, Rheinstetten,
Germany) equipped with a BGA12S gradient system and
interfaced to a Bruker Paravision 5.0 console. A Bruker
four-element 1H surface coil array was used as the recei-
ver and a Bruker 72-mm linear-volume coil as the trans-
mitter. The rat was anesthetized in an animal chamber
using a gas mixture of O2 (1 L/min) and isoflurane
(2.5%). The animal was then placed prone in an animal
holder and the RF (radio frequency) coil was positioned
and fixed over the brain of the animal. The animal holder
was moved to the center of the magnet and the isoflurane
level was changed to 2%. The level of isoflurane was fur-
ther adjusted based on the respiration rate changes of the
animal for the remainder of the experiment. A MR com-
patible small-animal monitoring and gating system (SA
Instruments, Inc, Stony Brook, NY, U.S.A.) was used to
monitor the animal respiration rate and body tempera-
ture. The animal body temperature was maintained at
36–37°C using warm water circulation. A three-slice
(axial, mid-sagittal, and coronal) scout using a fast low
angle shot (FLASH) sequence33,34 was obtained to localize
the rat brain. A fast shimming procedure (FASTMAP)
was used to improve the B0 homogeneity in the region of
interest.35 Both proton density- and T2-weighted images
were obtained using a 2D rapid acquisition with relaxa-
tion enhancement (RARE) sequence36 in the axial plane
of the brain with TR/TEeff1/TEeff2 = 5500/9.56/47.82 msec,
RARE factor = 4, field of view (FOV) = 30 9 25 mm2,
slice thickness = 1 mm, in-plane resolution = 117 9
117 lm2, number of averages = 1 for anatomic refer-
ences. For 1H MRS, adjustments of all first- and second-
order shims over the voxel of interest were accomplished
with the FASTMAP procedure. A Bruker outer volume
suppression combined with point-resolved spectroscopy
(PRESS) sequence37 was used for signal acquisition from
left and right hippocampus, respectively, with the voxel
size of 3 9 3 9 3 mm. The rest of the parameters were
TR/TE = 2500/20 msec, spectral bandwidth = 4 kHz,
number of data points = 2048, number of averages = 320.
We performed volumetric MRI studies to reveal differ-
ences in hippocampal volume between the LCR and HCR
rats. High-resolution multislice two-dimensional (2-D)
volumetric MRI was used to elucidate structural changes
present in the hippocampus of LCR and HCR rats. We
used coronal sections to manually outline regions of
interest (ROIs), including the dorsal hippocampus and
the lateral and basolateral amygdalae from the both hemi-
spheres. ImageJ (wsr@nih.gov) was used as the software
package for image processing. Anatomical information
was obtained from the Paxinos and Watson rat brain
atlas.38 Using the atlas-based segmentation approach, we
computed the volume of the hippocampus for each ani-
mal. The protocol for measuring the hippocampal volume
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was performed as previously described.39 Drawings were
made using a twofold magnification to construct the ROI,
and checked at original size to determine accuracy. ROIs
were only constructed on slices in which the hippocampal
structure was visually and reliably distinct. Thus, although
part of CA3 and the subiculum was visible beyond the
respective rostral and caudal boundaries, they were not
included in the analyses for the purpose of reliability. The
hippocampus was measured on five consecutive slices in
all animals, over a distance of roughly 2.16 mm to
7.20 from Bregma. The slices were examined from ros-
tral to caudal. The narrowing of the ventral hippocampal
commissure, the rounding of the dorsal third ventricle,
and the appearance of both CA3 and the dentate gyrus
was taken to represent the rostral boundary of the hippo-
campus. Measurement of hippocampal volume started
around 2.16 mm from the Bregma and ended around
7.20 mm from the Bregma. Volumes were measured in
pixels.
Stereological cell counting
We used the unbiased stereological methods and a com-
puter-assisted system (Stereo Investigator; MicroBright-
filed Bioscience, Williston, VT, U.S.A) coupled to an
Olympus microscope to obtain estimates of the total
number of neurons in five major subdivisions of the
mouse hippocampus as described previously.40 The sys-
tem uses a three-dimensional probe for counting neuro-
nal nuclei called the optical dissector and a systematic
uniform sampling scheme called the fractionators. Hippo-
campal sections (40 lm) were placed sequentially in wells
and stained with cresyl violet. The reference point for the
start of the measurement grid (260 9 80 mm) was the
neuron from the CA1 closest to the corpus callosum.
Neurons were counted at 1009 amplification.
Spontaneous spatial novelty preference test
on the Y maze
The LCR and HCR rats had no previous experience of
any maze testing. The spontaneous spatial novelty prefer-
ence test was conducted using a Y maze. Rats were
assigned two arms (“start arm” and “other arm”), to
which they were exposed for 5 min during the first phase
of the test (the exposure phase). During this exposure
phase, the entrance to the third arm of the maze was
blocked. The rat was removed from the maze and
returned to its home cage for 2 min. The rat was then
returned to the maze for the test phase (10 min), during
which it now had ad libitum access to all three arms of
the maze. Entry into an arm was defined when a rat
placed all four paws into an arm. A rat was considered to
have left arm if all four paws were placed outside that
arm. The amount of time a rat spent in each of the arms
of the maze and the number of entries into each arm was
recorded during both the exposure and test phases. For
the test phase, a discrimination ratio (novel arm/[novel
arm + other arm]) was calculated for both arm entries
and time spent in arms.
Isolation of brain mitochondria
Hippocampal mitochondria from rat brain were isolated
using a Percoll (Amersham Biosciences, Piscataway, NJ)
gradient centrifugation as described previously.25 Briefly,
hippocampal tissue of rat brain was homogenized in ice-
cold mannitol–sucrose (MS) buffer (225 mmol/L manni-
tol, 75 mmol/L sucrose, 5 mmol/L HEPES, 1 mmol/L
EGTA, 1 mg/mL fatty-acid-free bovine serum albumin
[BSA], pH 7.4 at 4°C). The homogenate was centrifuged
at 1300 g for 3 min, and the pellet was resuspended and
centrifuged again at 1300 g for 3 min. The pooled super-
natants was centrifuged at 22,200 g for 8 min, the crude
mitochondrial pellet was resuspended in 15% Percoll,
and layered on a pre-formed gradient of 40% and 24%
Percoll. After centrifugation at 31,700 g for 8 min, the
mitochondria were collected from the interface of the
lower two layers, diluted with isolation medium, and
centrifuged at 16,700 g for 10 min. The purity of Per-
coll-isolated mitochondria was further confirmed by
transmission electron microscopy and western blot analy-
sis with various subcellular protein markers. The Percoll-
purified mitochondrial pellet was used for respiratory
chain complex assay and western blot analysis. For mea-
suring respiration, the crude mitochondrial pellet, con-
taining primarily free (nonsynaptic) mitochondria plus
synaptosomes, was then resuspended in 10 mL of MS
buffer, using gentle trituration with a disposable Pasteur
pipette. A 13.5 lL of 10% (wt/vol) digitonin (Calbio-
chem, Billerica Massachusetts U.S.A.) in dimethylsulfox-
ide (DMSO) was added and gently mixed on ice for
3 min. This suspension material was spun at 22,000 g
for 8 min. The mitochondrial pellet was then resus-
pended to a final volume of 1.5 mL of MS buffer plus
BSA and centrifuged at 22,000 g for 10 min at 4°C in a
microfuge. The resulting mitochondrial pellet was resus-
pended in MS without EGTA. Protein concentrations
were determined in triplicate by standard Bradford
method employing a BSA standard curve.
Mitochondrial respiration
Isolated mitochondria were added at a final concentration
of 0.5 mg protein/mL to a thermostatically controlled O2
electrode chamber (Hansatech Instruments, Norfolk,
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England) equipped with magnetic stirring and containing
0.5 mL of respiration buffer (125 mmol/L KCl, 20 mmol/L
Hepes and 2 mmol/L K2HPO4 at pH 7.4, 37°C). Malate
and Glutamate were used as substrates to assess Complex
I-mediated respiration. State 3 respiration was initiated by
the addition of 1.0 mmol/L ADP. Approximately 2 min
later, state 3 respiration was terminated and state 4o
respiration (resting) was initiated with addition of
1.25 lg/mL oligomycin, an inhibitor of the mitochondrial
ATP synthase. The maximal rate of uncoupled respiration
was subsequently measured by the addition of 65 nmol/L
carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone
(FCCP), which is a protonophore uncoupling molecule.
Rates are an average of 4–6 independent experiments for
complex I respiration. One of seven experiments was
excluded from analysis because respiratory rates were >2.7
and 16.7 standard deviations from the mean for HCR
and LCR state 3 respiration, respectively. Rates between
HCR and LCR hippocampi were statistically compared
using a two-way unpaired Student’s t-test. P < 0.05 was
considered significant.
Carbonate extraction assay
The mitoplast was prepared followed by a carbonate
extraction assay as described previously.25 Mitochondria
were resuspended in buffer A 10 mmol/L phosphate buf-
fer, pH 7.4, 1 mmol/L ethylene glycol-bis (b-aminoethyl
ether)N,N,N,N-tetraacetic acid (EGTA), 1 mmol/L PMSF,
using a Dounce homogenizer, further diluted to a protein
concentration of ~0.1 mg/mL, and kept on ice for
20 min. Mitoplasts were resuspended in buffer A contain-
ing 8.6% (w/v) sucrose and recovered from the 33%/47%
interphase, washed and resuspended in buffer B
(20 mmol/L 3-(N-morpholino) propanesulfonic acid, pH
7.2, 1 mmol/L EGTA, 1 mmol/L PMSF), and broken by
freeze/thaw cycles followed by sonication. The inner
membrane and matrix fractions of the mitoplasts were
separated by centrifugation at 100,000 g for 30 min. The
inner membrane fraction was further subjected to alkaline
treatment (0.1 mol/L Na2CO3, pH 11.5 for 30 min) and
then centrifuged at 144,000 g at 4°C to obtain integral
inner membrane proteins.
Respiratory chain complex assay
Respiratory chain complex activity was measured on
native protein complexes from purified rat hippocampal
mitochondria using 3–12% native-PAGE as described
previously.41 Briefly, purified mitochondrial proteins
(100 lg) were solubilized with 150 lL of buffer
(50 mmol/L NaCl, 50 mmol/L imidazole/HCl, 2 mmol/L
6-aminohexanoic acid, 1 mmol/L EDTA, pH 7.0)
containing a dodecyl-b-D-maltoside (Sigma, St. Louis,
MO U.S.A) to a final concentration of 2.5 g per g pro-
tein. After incubation for 30 min on ice, samples were
centrifuged at 20,000 g for 20 min and were supple-
mented with 20 lL of 50% (w/v) glycerol, 0.1% Ponceau
S. Equal sample amount (20 lg) was applied to native gel
(Invitrogen, Grand Island, NY, U.S.A.). The anode buffer
(25 mmol/L imidazole/HCl, pH 7.0) and cathode buffer
(50 mmol/L tricine, 7.5 mmol/L imidazole, 0.05% sodium
deoxycholate, pH 7.0) were used for native electrophore-
sis. The native gel was used for in-gel catalytic activity
assay. The gel was assayed for complex I activity in assay
buffer (25 mg of nitrotetrazolium blue [NTB] and 100 lL
of NADH [10 mg/mL] added to 10 mL of 5 mmol/L
Tris/HCl, pH 7.4). After 3–10 min the reaction was
stopped using the fixing solution (50% methanol, 10%
acetic acid) and scanned for densitometric quantitation.
For complex II assay, the gel was incubated with assay
buffer containing 200-lL sodium succinate (1 mol/L),
8 lL of phenazine methosulfate (250 mmol/L dissolved in
DMSO), and 25 mg of NTB in 10 mL of 5 mmol/L Tris/
HCl, pH 7.4. After 30 min of incubation the reaction was
stopped in fixing solution and scanned for densitometric
quantitation. Complex III activity was analyzed by incu-
bating the gel in complex III assay buffer (5 mg of diam-
inobenzidine dissolved in 10 mL of 50 mmol/L sodium
phosphate, pH 7.2). After 60 min of staining, the gel was
scanned for densitometric quantitation. For complex IV
assay, the gel was incubated with the complex III assay
buffer supplemented with 100 lL of horse heart cyto-
chrome c (5 mmol/L) for 30 min followed by densitomet-
ric quantitation.
Mitochondrial DNA copy number and
mitochondrial DNA damage
Genomic DNA was isolated from the hippocampus of
LCR and HCR rat brains. Mitochondrial DNA copy num-
ber was determined by PCR of two mtDNA targets: a
197-bp ND1 gene and a 199-bp CytB gene and the Ct
values were compared with a standard plasmid carrying
ND1 and CytB mtDNA fragments. Nuclear DNA copy
number was determined by PCR for a nuclear DNA
175-bp B2M gene target and the Ct values were compared
with a plasmid carrying a B2M nuclear gene fragment.
The ratio of mtDNA/nDNA was calculated by 2 9
(ND1 Copies/20 ng DNA)/(B2M Copies/20 ng DNA);
and by 2 9 (CytB Copies/20 ng DNA)/(B2M Copies/
20 ng DNA). Damage to mtDNA was measured by long-
range (LR) Q-PCR of an 8.9-kb mtDNA target. This was
based upon the principle that DNA damage slows down
or blocks the progression of DNA polymerase along a
template. PCR product was generated at three different
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DNA concentrations to ensure the amplification was in
the exponential phase and the products were quantified
by PicoGreen fluorometry. The amount of PCR product
was quantified and the amount is inversely related to
mtDNA damage.
Western blot analysis of mitochondria
Purified mitochondria were incubated with protease K
(for 25 min at 0°C) to remove the cytosolic proteins
loosely associated with the outer mitochondrial mem-
brane. The purified mitochondrial pellet was lysed in a
buffer containing 50 mmol/L HEPES, 100 mmol/L NaCl,
1% NP-40, and a mixture of protease inhibitors (Roche
Molecular Biochemicals, Mannheim Germany) and phos-
phatase inhibitors (Sigma). After homogenizing with 20
strokes using a Dounce homogenizer ( Bellco Glass, Vine-
land, NJ, U.S.A.), mitochondrial lysates were centrifuged
at 20,000 g, and the supernatants were used for western
blot analysis with anti-PGC-1a,25 anti-SIRT1 (sc-15404;
Santa Cruz Biotechnology, Dallas, Texas, U.S.A.), anti-
TFAM (NBP1-71648; Novus Biologicals, Littleton, CO,
U.S.A.), anti-pTau Ser404 (sc-12952; Santa Cruz Biotech-
nology), anti-pTau Ser396 (44752; Invitrogen), anti-pTau
Ser262 (ab131354; AbCam, Cambridge, MA. U.S.A.),
anti-pTau Thr 231 (AB 9668; Millipore, Billerica, MA,
U.S.A.), anti-Histone H3 (ab1791; AbCam), anti-GAPDH
(2118; Cell Signaling), or anti-HSP 60 (4870; Cell Signal-
ing) antibodies. Horseradish peroxidase-conjugated sec-
ondary antibodies were purchased from Pierce
Biotechnology, Rockford, IL, U.S.A. Antibody binding
was detected by using the SuperSignal chemiluminescence
kit (Pierce) and an Alpha, Innotech imaging system
(Santa Clara, California, U.S.A).
Immunoelectron microscopy
LCR and HCR rats were perfused with saline followed by
4% paraformaldehyde in 0.1 mol/L of phosphate buffer.
Rat hippocampus tissue was dissected under an operating
microscope, mounted in the slot of a small screw, and
snap frozen in liquid nitrogen. Ultrathin sections (70–
100 nm) from rat hippocampus tissue were incubated
concurrently with primary antibodies against p-Tau
Ser404 (1:50) or Ser396 (1:50) for 1 h and followed by
incubation with appropriate 10 nm immunogold-conju-
gated secondary antibodies (Jackson ImmunoResearch,
Laboratory, West Grove, PA, U.S.A.) for 1 h. Sections
were fixed with 2.5% glutaraldehyde, counterstained with
4% neutral uranyl acetate, embedded in 1.25% methyl
cellulose, then observed using a JEOL JEM 1210 electron
microscope (JEOL USA, Inc, Peabody, MA, U.S.A.) at
80 kV.
Statistics
The results are presented as mean  SEM. A statistical
analysis was performed based on two-tailed t-test with the
significance level at P ≤ 0.05 or P ≤ 0.001.
Results
Whole-body metabolic parameters
When young, the LCR and HCR rats differ by 6-fold for
intrinsic aerobic running capacity, aged LCR were signifi-
cantly more obese than HCR, as indicated by higher body
weight and percent body fat (Table 1, P < 0.001). The
value of VO2 over 24 h, corrected for lean body mass, an
indicator of energy expenditure, was significantly lower in
the LCR than the HCR rats (Table 1, P < 0.001) but there
was no difference in the RQ between LCR and HCR rats.
Both fasting and nonfasting glucose were significantly
higher in the LCR than HCR rats (Table 1, P < 0.001).
1H MRS
LCR and HCR rats were subjected to in vivo 1H MRS of
the dorsal hippocampus. 1H MRS allows the noninvasive
assessment of altered brain metabolic profile42 and mea-
surement of the biomechanical changes associated with
central nervous system injury.43 All data were analyzed
using the LC-Model package44 and the results are shown
(Fig. 1). There was a significant difference in the hippo-
campal MRS metabolic profile between LCR and HCR rats.
Creatine and phosphocreatine (Cr) were used as the inter-
nal standard for comparison because they remain relatively
Table 1. Metabolic values in HCR and LCR rats.
HCR (N = 10) LCR (N = 10)
Body weight (g) 407.69  9.46 577.01  25.67*
Percent body fat 12.06  0.71 23.40  1.21*
VO2 over 24 h corrected
for lean body mass
(mL/kg)
1674.40  33.50 1447.0  39.70*
Respiratory quotient
(VCO2/VO2) over 24 h
0.90  0.01 0.90  0.02
Fasting glucose (mg/dL) 67.27  1.94 82.72  2.27*
Nonfasting glucose
(mg/dL)
97.1  2.65 115.6  4.27*
Insulin (ng/mL) 0.62  0.19 0.93  0.36
Triglyceride (mg/dL) 87.64  12.59 98.23  58.41
Cholesterol (ng/mL) 1.36  0.18 1.54  0.18
HDL cholesterol (lg/mL) 0.88  0.15 0.74  0.08
The rest of the comparisons are not statistically different. VO2, oxygen
consumption; VCO2, CO2 production; HDL, high-density lipoprotein.
*P < 0.001 as compared to HCR.
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constant. The top panel of Figure 1 shows a representative
1H MRS spectrum of LCR and HCR hippocampus. The
glutamate/tCr (P < 0.01), myo-inositol/tCr (P < 0.01), tau-
rine/tCr (P < 0.0001), and glycerophosphocholine and
phosphocholine/tCr (P < 0.01) ratios were significantly
higher in LCR than HCR rats (Fig. 1). A decreasing trend
was observed in glutamine/tCr (P < 0.08) for the LCR rats
compared to the HCR rats (Fig. 1). There was no difference
in the glucose/tCr and N-acetylaspartate (NAA)/tCr ratios
between LCR than HCR rats (Fig. 1).
Morphological MRI and histology of the
hippocampus
Volumetric analysis showed a significant change in the
relative sizes for ROIs analyzed in LCR rats versus HCR
Figure 1. Concentrations of metabolites in the dorsal hippocampus are altered in LCR rats compared to HCR rats. (A) Example of spectrum
from the dorsal hippocampus of a LCR rat (top) and an HCR rat (bottom). (B) Neurochemical profile of LCR and HCR rats (N = 9/group).
The ratios of in vivo mean metabolite concentrations of glucose, glutamine (Gln), glutamate (Glu), myo-inositol (Ins),
glycerophosphorylcholine (GPC) and phosphorylcholine (PCh), N-acetylaspartate (NAA), and Taurine (Tau) relative to total creatine (tCr) were
computed for each voxel and a paired one-tail Student’s t-test was performed to compare the difference between the neurochemical
profiles of the LCR and the HCR rats. Data represent the mean  SEM for spectra from the left and right hippocampus. LCR, low-capacity
runner; HCR, high-capacity runner.
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rats. The mean total hippocampal volume of the LCR rats
was markedly decreased compared to the HCR rats
(Fig. 2A). Unbiased stereological cell counting confirmed
significant cell loss in the CA1 region of LCR rats com-
pared with HCR rats (Fig. 2B).
Spontaneous spatial novelty preference test
on the Y maze
Using a Y maze, we determined differences in cognitive
abilities dependent on hippocampal function between
LCR and HCR rats. The Y maze assesses rapidly acquired,
short-term spatial memory and relies on the fact that nor-
mal rats prefer novel over familial spatial environments.
In this task, animals explored two arms and then were
returned to the home cage. During the exposure phase,
LCR and HCR rats made a similar number of total arm
entries. The number of arm entries and the amount of
time spent exploring the two arms (the start and other
arms) did not differ. During the test phase, HCR rats,
compared with LCR rats, showed a strong preference for
the novel arm (previously unvisited arm). Discrimination
ratio analysis showed that the LCR rats had less prefer-
ence for the novel arm (P < 0.05) than the HCR rats
(Fig. 3).
Mitochondrial electron transport chain
activity, function, mitochondrial DNA copy
number, and mitochondrial DNA damage
Impairment of mitochondrial respiratory chain complex
activity has been well documented in diabetes and AD
patients.10,18,19 Therefore, we measured the changes in the
respiratory chain complex activity and respiratory func-
tion in hippocampal mitochondria between LCR and
HCR rats. Using the mild nonionic detergent dodecy-b-D-
maltoside (DDM), four complexes (complex I–IV) of
mitochondrial oxidative phosphorylation were solubilized
as individual membrane protein complexes, namely,
NADH:ubiquinone reductase (complex I, ~740 kDa), suc-
cinate:ubiquinone reductase (complex II, ~200 kDa),
ubiquinol:cytochrome c reductase (complex III, ~300 and
600 kDa), and cytochrome c oxidase (complex IV, ~240
and 620 kDa) (Fig. 4A). In comparison with the HCR
rats, LCR rats had significantly lower hippocampal com-
plex III activity (with mean reduction of 30%) (Fig. 4B).
In contrast, LCR rats had a nonsignificant trend for lower
complex I, II, and IV activities (with mean reduction of
less than 5%) compared with HCR rats (Fig. 4B). We
then performed isolated hippocampal mitochondrial res-
pirometry at physiological temperature (37°C) to assess
possible mitochondrial functional differences between
HCR and LCR rats. Hippocampal mitochondria from
LCR rats respiring on complex I substrates malate and
glutamate had a slight but significantly decreased state 3
respiration (P < 0.05, mean reduction of 11.8%). A simi-
lar but nonsignificant reduction of ~10% was observed
Figure 2. Hippocampal volume and neuronal number are reduced in LCR rats compared with HCR rats. (A) The total hippocampal volume on
MRI (total volume for left and right hippocampus) was measured in LCR (N = 13) and HCR rats (N = 14). (B) Unbiased stereology measurement of
the total volume of normal neurons in the CA1 region of the hippocampus shows that the neuron count is significantly reduced in LCR compared
to HCR rats (N = 5). *P < 0.05. LCR, low-capacity runner; HCR, high-capacity runner.
Figure 3. LCR rats display a reduced spatial novelty preference
compared to HCR rats. A discrimination ratio (100 9 novel/
[novel + other]) was calculated for both the number of arm entries
(A) and the time spent in the arm (B) for both LCR and HCR rats
(N = 9). *P < 0.05. LCR, low-capacity runner; HCR, high-capacity
runner.
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with complex II substrate succinate in the presence of
complex I inhibitor rotenone. We also determined
changes in mitochondrial DNA copy number and mito-
chondrial DNA damage (e.g., CytB gene) in the hippo-
campal mitochondria between LCR and HCR rats.
Genomic DNA was isolated from hippocampus of LCR
and HCR rat brains. Mitochondrial DNA copy number
was determined by PCR of two mtDNA targets: a 197-bp
ND1 gene and a 199-bp CytB gene. Mitochondrial DNA
damage was measured by LR Q-PCR of an 8.9-kb
mtDNA target. The results revealed that there is no signif-
icant difference in mitochondrial DNA copy number or
mitochondrial DNA damage between LCR and HCR rats
(Table 2).
Mitochondrial regulatory proteins and
phospho-Tau
We determined whether the protein levels of PGC-1a,
SIRT1, and TFAM, the major regulators of mitochondrial
biogenesis and metabolism, are altered in LCR rats com-
pared with HCR rats. Hippocampus tissues obtained from
Figure 4. Reduced mitochondrial respiratory chain complex III activity and state 3 respiration in LCR rats compared with HCR rats. (A)
Hippocampal mitochondria of LCR and HCR rats were solubilized with dodecyl-b-D-maltoside (DDM) and mitochondrial protein lysates (50 lg)
were loaded onto the blue native gel wells. After electrophoresis, one gel was stained with Coomassie blue, the other gels were subjected to
“In-gel activity analysis” to reveal the presence of complex I, II, III, or IV. H, HCR; L, LCR. (B) Densitometric quantification of each protein band
(N = 5). *P < 0.05. (C) Oxygen consumption rates for hippocampal mitochondria isolated from LCR and HCR rats. Data are presented as the
average OCR  SE. *P < 0.05. LCR, low-capacity runner; HCR, high-capacity runner.
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LCR and HCR rats were analyzed by western blotting
using antibodies against PGC-1a, SIRT1, and TFAM
(Fig. 5A). The results revealed that there is a significant
decrease in PGC-1a (35 kDa), SIRT1, and TFAM protein
levels in the hippocampus samples from LCR rats com-
pared with HCR rats (Fig. 5B). Increased hyperphosph-
orylated tau (p-Tau) has been reported in diabetes.14,45
Therefore, we determined whether p-Tau is increased in
the hippocampus of LCR rats. Mitochondria were puri-
fied from the hippocampus of LCR and HCR rats. Puri-
fied mitochondria were treated with protease K to remove
the cytosolic proteins that are loosely attached to the
mitochondrial outer membrane and were subjected to
western blot analysis with various anti-P-Tau (Ser404,
Ser396, Ser262, and Thr231) antibodies. We verified the
purity of the mitochondrial fraction using western blot
analysis with anti-HSP60, Histon H3, and GAPDH anti-
bodies (Fig. 5C), as well as transmission electron micros-
copy (Fig. 5E and F). Compared to the crude
mitochondrial fraction that contains various subcellular
organelles (Fig. 5E), we observed only mitochondria in
the Percoll-purified mitochondrial fraction used for wes-
tern blot analysis (Fig. 5F). Results showed that there is
an accumulation of p-Tau (Ser404, Ser396, Ser262, and
Thr231) in the hippocampal mitochondria of LCR but
not HCR rats (Fig. 5C). We further investigated the
submitochondrial localization of p-Tau by performing a
carbonate extraction assay. The purified mitochondrial
inner membrane and matrix fractions of the mitoplasts
were subjected to western blot analysis with anti-p-Tau
Ser404 antibody. Results showed a presence of p-Tau in
the both soluble and pellet fractions (Fig. 5D). We veri-
fied the purity of the matrix fraction and the inner mem-
brane fraction using western blot analysis with anti-Grp
75 (a mitochondrial matrix marker), anti-NDUFV2 (a
mitochondrial inner membrane marker), anti-Histone
H3, and anti-GAPDH antibodies.
Immunoelectron microscopy analysis of LCR and
HCR hippocampal tissue with anti-p-Tau (Ser404 and
Ser396) antibodies showed apparent localization of p-
Tau protein in the mitochondria of LCR (Fig. 5G and
H) but not HCR rats (Fig. 5I and J). To quantitatively
estimate the immunogold labeling produced by the p-
Tau Ser404 or Ser396 antibody, we counted the total
number of immunogold particles observed within mito-
chondria (1173 or 1295 gold particles from 30 mito-
chondria of three pellets were counted total in the
section labeled with p-Tau Ser404 or Ser396, respec-
tively). Quantification data showed that 13  3 or
14  5 particles/mitochondria were observed in the sec-
tion labeled with p-Tau Ser404 or Ser396, respectively.
No gold particles were detected in the negative controls
when the anti-p-Tau antibodies (Ser404 and Ser396)
were omitted and secondary antibody included (data not
shown). We also observed some p-Tau Ser404 and
Ser396 immunoreactivities outside the mitochondria. We
verified our immunoelectron microscopy analysis of LCR
rat hippocampal tissue with anti-voltage-dependent
anion channel (VDAC) antibody as a positive control
(Fig. S1). Double labeling immunoelectron microscopy
analysis with antibodies against p-Tau Ser396 or Ser404
and VDAC revealed that these two proteins colocalize in
the hippocampal mitochondria of LCR rat brain (Fig.
S1). We also verified the specificity of p-Tau Ser404 and
Ser396 antibodies using western blot analysis (Fig. S2).
Neither p-Tau Ser404 nor Ser396 immunoreactivity was
detected in the controls, when the samples were pre-
treated with lambda protein phosphatase or antibodies
were preincubated with phosphopeptide that was derived
from human Tau around the phosphorylation site of
serine 396 or 404 (Fig. S2).
Discussion
This study demonstrates that impaired cognitive function
and neurodegeneration are observed in the hippocampus
of aged LCR rats. In parallel to these abnormalities, there
is an alteration in the hippocampal metabolic profile, a
decrease in mitochondrial respiration, complex III activity,
mitochondrial regulatory protein levels, and an accumula-
tion of hyperphosphorylated Tau within mitochondria.
Importantly, the aged LCR rats also exhibit many
Table 2. Mitochondrial DNA copy number and DNA damage in HCR and LCR rat.
Tissue B2M copies/20 ng DNA ND1 copies/20 ng DNA Ratio (mtDNA/nDNA)
LCR 22,000  2014 39,220,000  120,000 1945  224
HCR 21,500  1960 38,750,000  119,000 1897  205
Tissue B2M copies/20 ng DNA CytB copies/20 ng DNA Ratio (mtDNA/nDNA)
LCR 22,000  2014 38,890,000  121,000 2012  205
HCR 21,500  1960 37,967,000  119,750 1978  198
Tissue LR DNA amplified LR DNA amplified/106 ND1 copies LR DNA amplified/106 CYTB copies
LCR 2088  218 91  10 88  8
HCR 2175  207 94  12 91 + 9
LCR, low-capacity runner; HCR, high-capacity runner; LR, long range.
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characteristics common to humans with metabolic syn-
drome with mild type 2 diabetes mellitus. These include
increased body weight and adiposity, increased fasting
and nonfasting glucose, and decreased aerobic capacity
(VO2). Thus, this animal model presents a novel pheno-
type for cognitive decline and neurodegeneration that
would model similar changes seen in human metabolic
syndrome with mild type 2 diabetes mellitus.4 Further-
more, the impaired mitochondrial function and reduced
mitochondrial transcription factors would be consistent
with a metabolic phenotype that results in impaired hip-
pocampal neuronal function and degeneration. In addi-
tion to this possibility, previous studies indicated that
mitochondrial function is impaired in skeletal muscle and
liver in LCR rats46,47 and presumably most if not all other
locations. Therefore, it is axiomatic that the status of
the hippocampus is an admixture of local and remote
influences.
Figure 5. There is a significant decrease in the protein levels of PGC-1a, SIRT1, and TFAM in the hippocampus of LCR compared to HCR rats and
an accumulation of hyperphosphorylated p-Tau in the hippocampal mitochondria of LCR but not HCR rats. (A) Total protein lysates (25 lg) from
the hippocampus of LCR and HCR rats were subjected to SDS-PAGE gel followed by immunoblotting with anti-PGC-1a, SIRT1, TFAM, and HSP 60
antibodies. (B) Densitometric quantification and normalization to the HSP 60 level in the corresponding samples (N = 5). *P < 0.05. (C) Lysates
(25 lg) from purified hippocampal mitochondria were subjected to SDS-PAGE gel followed by immunoblotting with various anti-phosphoTau
(pSer404, pSer396, pSer262, and pThr231) antibodies. Lanes 1, 2, and 3 represent three different rats. (D) Western blot analysis of mitochondrial
inner membrane (Mem.) and matrix (Sol.) probed with antibodies directed against pSer404, NDUFV2, Grp 75, Histone H3 (a nuclear marker), and
GAPDH (a cytosolic marker). We verified the purity of the mitochondrial fraction using western blot analysis with anti-HSP60, Histone H3, and
GAPDH antibodies (C and D), as well as transmission electron microscopy (E and F). Transmission electron microscopy of the crude mitochondrial
pellet (E) and the Percoll-purified mitochondrial pellet (F) used for western blot analysis (C). (G, H, I, and J) Immunoelectron microscopy of
mitochondrial hyperphosphorylated p-Tau Ser404 (G) and Ser396 (H) localization in the hippocampus of LCR rats. Black arrow indicates
hyperphosphorylated p-Tau immunogold labeling. Neither hyperphosphorylated p-Tau Ser404 (I) nor Ser396 (J) immunoreactivity was detectable
in the hippocampus of HCR rats. LCR, low-capacity runner; HCR, high-capacity runner.
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We observed a significant increase in glutamate/tCr in
the hippocampus of live LCR rats compared with HCR
rats. An increased extracellular glutamate concentration at
the synapse level has been implicated in hippocampal cell
death.48,49 Accordingly, our unbiased stereological analysis
and behavioral measurement showed a significant cell loss
in the CA1 region and cognitive impairment in LCR rats
compared with HCR rats. There were also increases in the
myo-inositol/tCr and taurine/tCr ratios in the hippocam-
pus of LCR rats compared with HCR rats. Previously,
increased myo-inositol has been shown to be related to
the activation of microglia in an animal model of AD.50
Moreover, taurine has been shown to protect neurons
against both Ab- and glutamate receptor agonist-induced
toxicity.51,52 Interestingly, taurine is significantly increased
in LCR rats. Taurine is an abundant amino acid present
in brain, has antioxidant properties, and is known to act
as an osmoregulator and regulator of mitochondrial func-
tion. Although taurine is decreased in AD brain, its
chemical structure is similar to 3-amino-1-propanesulfon-
ic acid, a compound which interferes with beta-amyloid
peptide aggregation. Furthermore, taurine slightly
decreases beta-amyloid peptide aggregation53 and the high
levels observed in LCR hippocampus would be consistent
with a feedback response to ongoing neurodegeneration.
Both myo-inositol and taurine are major osmolytes in the
brain,54,55 and thus an alteration in the levels of these
metabolites could well indicate changes in cell volume
regulation. Consistent with this concept, it has been
reported that hippocampal volume in humans with AD is
smaller than in controls and the degree of volume
decrease is associated with greater severity of dementia.56
Thus, the high levels of taurine and/or myo-inositol
observed in LCR hippocampus may contribute to hippo-
campal volume loss in these animals. In accord with this
possibility, we observed a significant decrease in hippo-
campal volume in LCR rats compared with HCR rats.
Alterations in membrane synthesis and degradation can
produce changes in the glycerophosphocholine and phos-
phocholine/tCr peak, as these are breakdown products,
and the latter is a precursor for phosphatidylcholine, a
major component of cell membranes. Increased levels of
glycerophosphocholine and phosphocholine have been
previously reported in AD brain.57 Similarly, we observed
a significant increase in the glycerophosphocholine and
phosphocholine/tCr peak in the hippocampus of LCR rats
compared with HCR rats. Previously, inhibition of mito-
chondrial bioenergetics in neuronal cells has been shown
to accelerate phosphatidylcholine synthesis and break-
down.58 This suggests the presence of alterations in cell
membrane regulation in the LCR rats, which may be
implicated with changes in mitochondrial function in
these animals.
In AD and diabetes patients, a neuronal loss in the CA1
region of hippocampus and cognitive impairment has been
documented in many studies.59,60 The medial prefrontal
cortex receives projections directly from the intermediate
CA1 region of the hippocampus and this link may be criti-
cal for spatial navigation.61 Accordingly, we observed neu-
ronal loss in the CA1 region of the hippocampus and
impairment of spatial memory in the LCR rats compared
with HCR rats. Consistent with our results, a recent study
reported that in comparison with HCR rats, LCR rats show
impaired cognitive function, but no impairment of motor
running.62 Overall, the findings demonstrate that promi-
nent metabolite alterations occur in the hippocampus of
LCR rats, which is similar to AD brains and may contrib-
ute to the development of hippocampal neurodegeneration
including neuronal loss, decreased hippocampal volume,
and cognitive dysfunction.
Previous studies in skeletal muscle and heart have
shown that the selection for low- and high-running
capacity led to significant differences in mitochondrial
function and content between LCR and HCR rats.8,63
Accordingly, our study in brain demonstrates that protein
levels of key mitochondrial regulators, PGC-1a, SIRT1,
and TFAM, were significantly decreased in LCR rats com-
pared with HCR rats. SIRT1 activity increases deacetyla-
tion, activates downstream PGC-1a,64 and also interacts
with TFAM in the mitochondrion.65 Both SIRT1 and
PGC-1a play an important role in mitochondrial regener-
ation, cellular metabolism, and longevity.64 TFAM is
essential for transcription, replication, and maintenance
of mtDNA.64 SIRT1 protects neurons against b-amyloid-
induced toxicity.66 In part, SIRT1 neuroprotection may
be because of improved energy homeostasis.67 Interest-
ingly, a T-to-C exchange in exon 1 of SIRT1, correspond-
ing to a leucine-to-proline mutation at residue 107 results
in metabolic dysfunction in humans68 indicating that fail-
ure of the SIRT1–PGC-1a axis and TFAM, as observed in
LCR rat hippocampal mitochondria, would further impair
metabolic and mitochondrial function in neurons and
aggravate neurodegeneration.
Hippocampal mitochondrial respiration on complex I
substrates was significantly decreased in LCR rats com-
pared to HCR rats, whereas complex II respiration was
not significantly different. Respiratory chain complex III
activity was significantly decreased in LCR rats. In con-
trast, respiratory chain complex I, II, or IV remained
unchanged in these animals. Unfortunately, we were
unable to determine respiratory chain complex V activity;
however, the fact that the FCCP-stimulated uncoupled
mitochondrial respiration was not different between LCR
and HCR suggests a possibility of dysfunction at the
level of complex V. Expression of complex III protein
component is putatively controlled by PGC-1a, thus
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reduced PGC-1a or SIRT1 could contribute to the
observed reduction in complex III activity in LCR rats.
Inhibition of complex III has been shown to cause gluta-
mate release from the nerve terminal.69 Our MRS data
exhibited a significant increase in glutamate levels in LCR
rats compared with HCR rats. This result suggests a
correlation between complex III deficiency and potential
glutamate-mediated excitotoxicity in LCR rats. In addi-
tion, the reduction in complex III activity in LCR would
likely lead to a greater exposure to mitochondria-derived
reactive oxygen species production and propagation of
mitochondrial dysfunction due to mitochondrial DNA
mutations. In accordance with this possibility, we
observed a significant reduction in state 3 respiration rate
in the hippocampus of LCR compared to HCR rats. This
raises the possibility of lower energy metabolism due to
impaired complex III activity and could be associated
with the divergence in hippocampal integrity observed in
the aged LCR and HCR rats. In support of this possibil-
ity, human pathological tissue studies have demonstrated
that reduction in the activity of respiratory chain complex
III and altered glucose metabolism are found in AD.10,70
Interestingly, we observed that there was no significant
difference in mitochondrial DNA copy number and DNA
damage between LCR and HCR rats. These results,
however, do not rule out the possibility that specific
mutations in the CYTB gene could contribute to mito-
chondrial impairment in LCR brains. Given the well-
established metabolic disease susceptibility of LCR rats,
our results suggest that a reduced complex III activity,
coupled with a reduced expression of transcriptional reg-
ulators, may play an important role in susceptibility to
neurodegeneration, providing further evidence of the
importance of the mitochondrial energy metabolism in
brain function.
Interestingly, this study demonstrated a previously
unreported deposition of hyperphosphorylated Tau in the
mitochondria of LCR rats, but not in HCR rats. Tau pro-
tein binds and stabilizes microtubules, and hyper-
phosphorylation diminishes the ability of tau to bind
microtubules, resulting in microtubule destabilization. In
addition, unbound hyperphosphorylated tau may be
localized to an abnormal subcellular region such as mito-
chondria, which could contribute to impaired electron
transport chain function and activity observed in LCR
rats. Previously, Tau transgenic mice have been shown to
exhibit deposition of hyperphosphorylated Tau, and
develop progressive age-related neurofibrillary tangles,
hippocampal neurodegeneration, and behavioral impair-
ments.70–72 Experimental diabetes has been shown to
exacerbate Tau pathology in a transgenic mouse model of
AD.45 Furthermore, mitochondrial dysfunction and oxi-
dative stress cause hyperphosphorylation of Tau, and
antioxidants that target mitochondria significantly reduce
phosphorylated Tau.73 These results suggest that meta-
bolic and specifically mitochondrial alterations found in
LCR brain may cause the increased hyperphosphorylation
of Tau, which would likely contribute to the hippocampal
neurodegeneration. Further research is required to deter-
mine the precise role of hyperphosphorylated Tau
deposition in the LCR mitochondria.
This study demonstrates that aged LCR rats exhibit
many AD features, including altered metabolism, mito-
chondrial abnormalities, neuronal loss, decreased hippo-
campal volume, and impaired cognitive function. Further
research is required to determine the precise interplay
and temporal relationship between the metabolic and
mitochondrial abnormalities in the LCR rat hippocampus
and neuronal dysfunction. The aged LCR/HCR models
used in the present investigation provide novel evidence
that metabolic dysfunction is associated with hippocampal
neurodegeneration. This is in agreement with previous
studies suggesting that defects in glucose, lipid, and insu-
lin metabolism affect cognitive function. Furthermore,
these metabolic defects may represent an early stage in
the progression of some neurodegenerative diseases in
humans such as AD. Given the fact that AD is sporadic
with unclear pathogenesis in the majority of affected peo-
ple, the abnormalities described in the LCR rat brain may
represent early targets for further understanding the path-
ophysiology and potential interventions in this debilitat-
ing disease.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Immunoelectron microscopy showing colocal-
ization of mitochondrial p-Tau Ser396 (A) or Ser404 (B)
with the voltage-dependent anion channel (VDAC), a
mitochondrial marker. White and black arrows indicate
VDAC (5 nm) and p-Tau Ser396 (10 nm) or p-Tau
Ser404 (10 nm) immunogold labeling in LCR rat hippo-
campal tissue.
Figure S2. Western blot analysis of extracts from LCR rat
hippocampal mitochondria using Tau (phosphor-Ser396
or 404) antibody (lanes 1 and 2) and the same antibody
preincubated with blocking peptide (lane 3). Antibody
was preincubated with phosphopeptide that was derived
from human Tau around the phosphorylation site of ser-
ine 396 (A) or 404 (B). The synthesized phosphopeptide
was derived from human Tau around the phosphorylation
site of serine 396 (Y-K-S(p)-P-V) or 404 (D-T-S(p)-P-R).
Lanes 1 and 3, untreated extracts of LCR rat hippocampal
mitochondria: lane 2, lambda protein phosphatase treated
extracts of LCR rat hippocampal mitochondria.
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